Completed
PHASE2
INTERVENTIONAL
NCT00425555
Study of Oral LBH589 in Adult Patients With Refractory Cutaneous T-Cell Lymphoma
View on ClinicalTrials.gov
Updated Dec 15, 2025
Brief Summary
This study will evaluate the safety and efficacy of LBH489B in adult patients with refractory Cutaneous T-Cell Lymphoma.
Interventions
Name:
Panobinostat
Type:
DRUG
Description:
Primary Outcomes
Measure:
Overall Response Rate of Participants Using the Modified Severity-Weighted Assessment Tool (mSWAT)
TimeFrame:
Baseline up to 6 Months of Follow up
Description:
Skin response was primarily classified based on an assessment using mSWAT, provided there was documented evidence of stable disease or better in lymph node/viscera.The mSWAT is a tool specifically developed to evaluate the extent of skin disease in CTCL (Olsen et al 2007).
Responses in the skin based on SWAT are defined as:
* Complete Response (CR): no evidence of skin disease
* Partial Response (PR): ≥ 50% decrease of the modified SWAT score compared with baseline
* Stable Disease (SD): Neither CR, PR, or PD as compared with baseline, i.e. change from baseline is less than a 50% decrease but also less than a 25 % increase in the modified SWAT score
* Progressive Disease (PD): ≥ 25% increase in the modified SWAT score compared with baseline.
Trial Information
NCT ID
NCT00425555
Status
Completed
Study Type
INTERVENTIONAL
Phases
PHASE2
Sponsor
Novartis Pharmaceuticals
Last Updated
December 15, 2025